How to balance the patient voice atop the shifting plates of HTAThe tectonic plates of healthcare technology assessment (HTA) have shifted – but where does the patient voice fit Share XHow to balance the patient voice atop the shifting plates of HTAhttps://pharmaphorum.com/views-and-analysis/how-to-balance-the-patient-voice-atop-the-shifting-plates-of-hta/
Rethinking access barriers to innovationMarket access issues don’t stop once a product has passed HTA – and this is especially true for Share XRethinking access barriers to innovationhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/rethinking-access-barriers-to-innovation/
Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcastEpisode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as Share XGalapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/galapago-uk-michael-smyth-rna/
Deep Dive: Market AccessIt’s fair to say this is the most interesting time ever for market access. Not only has COVID Share XDeep Dive: Market Accesshttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/
2021 market access prospects for FranceIn the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes Share X2021 market access prospects for Francehttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/
Okra says AI-based drug price predictor is 90% accurateUK artificial intelligence startup Okra Technologies has launched a new software platform that it claims can take the Share XOkra says AI-based drug price predictor is 90% accuratehttps://pharmaphorum.com/news/okra-ai-based-drug-price-predictor-90-accurate/
How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
Janssen: ‘Open dialogue’ needed with HTAs to improve accessThe world of life sciences is changing rapidly, and the traditional ways of assessing drugs may no longer Share XJanssen: ‘Open dialogue’ needed with HTAs to improve accesshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/janssen-open-dialogue-needed-with-htas-to-improve-access/
Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
